Jiangsu Hengrui Pharmaceuticals Co Ltd, a global pharmaceutical company focusing on scientific and technological innovation, announced on March 25 that it has entered into an exclusive license ...

In recent years, Merck has formed strategic partnerships with domestic industry leaders such as Wondfo Biotech, Hengrui Biopharma, and Abbisko Therapeutics to explore breakthrough treatments ...

Pfizer and AbbVie shares declined more than 4%, Merck dropped almost 4%, and Eli Lilly pulled back over 3% in early trading. Daily Merck & Company, Inc. Dow pharmaceutical components are leading ...

Lusaka [Zambia] / Mumbai (Maharashtra) [India], April 7: Merck Foundation, the philanthropic arm of Merck KGaA Germany marks 'World Health Day' 2025 in partnership with Africa's First Ladies who ...

Senator, Dr. Rasha Kelej, CEO of Merck Foundation shared, "For over last 13 years, our efforts at Merck Foundation have been to ensure equitable access to healthcare through education, training ...

4. Merck KGaA pays $85M to nab global rights for Abbisko's rare tumor drug after phase 3 win After bagging a positive phase 3 trial in tenosynovial giant cell tumors, Merck KGaA has expanded its ...

Merck KGaA is spending $85 million to get global commercialization rights to pimicotinib, a candidate for non-malignant tumors that it licensed from Abbisko Therapeutics. Eli Lilly is expanding its ...

Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics") announced that Merck has exercised the global commercialization option for pimicotinib (ABSK021), with an option exercise fee of USD85.0 million ...

SHANGHAI, China I March 31, 2025 I On April 1, 2025, Beijing Time, Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics”) announced that Merck has exercised the global commercialization option for ...

With the CSF-1R inhibitor space heating up, Merck KGaA has gone all-in on pimicotinib, paying Abbisko Therapeutics $85 million to secure the global license to the drug. The German pharma ...

(RTTNews) - Abbisko Therapeutics Co., Ltd. announced that Merck has exercised the global commercialization option for pimicotinib (ABSK021), with an option exercise fee of US$85.0 million ...